GlassScriptPhysician profile
Ashley E Fletcher
NPI 1619370632
$6,835.54
in general payments reported to CMS, 2019-2025
23 companies · $1,977 in 2025
The $1,977 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $2,191 · 2023: $1,385 · 2024: $1,068 · 2025: $1,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,429.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,813.85 | 2021-2025 | |
| Medtronic, INC. | $1,437.88 | 2021-2024 | Percept PC Brainsense |
| Pfizer INC. | $526.95 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $415.85 | 2022-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $380.26 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $216.85 | 2021-2023 | Emgality, Reyvow |
| Boston Scientific Corporation | $167.80 | 2023-2025 | General - Therapies, Vercise |
| Amgen INC. | $148.62 | 2021-2022 | |
| Kyowa Kirin, INC. | $129.69 | 2022-2024 | Nourianz |
| Novartis Pharmaceuticals Corporation | $90.94 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $89.88 | 2022 | |
| Abbott Laboratories | $87.50 | 2022-2023 | Infinity |
| Biogen, INC. | $84.90 | 2025 | Vumerity, Tysabri |
| Emd Serono, INC. | $62.37 | 2022-2025 | |
| Livanova USA, INC. | $28.06 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $25.62 | 2021 | |
| Mallinckrodt Hospital Products INC. | $23.54 | 2025 | Acthar |
| Neurelis, INC. | $21.76 | 2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $21.32 | 2025 | Xeomin, Ampyra, Inbrija |
| Catalyst Pharmaceuticals, INC. | $16.34 | 2024 | |
| Allergan, INC. | $16.26 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.36 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.94 | 2025 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.